Riskpilot← Back to searchSign inGet full accessAmplio Pharma AB
ABActiveOrg 5592371073LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2025
SEK 89K
-65% vs 2024
EBITDA margin
1368.5%
+4450% vs 2024
Equity ratio
39.6%
Financial strength
Net profit 2025
SEK 1M
+1086% vs 2024
| Revenue | SEK 89K | -65% |
| EBITDA | SEK 1,2M | +4450% |
| Net profit | SEK 1M | +1086% |
| Total assets | SEK 2,9M | +81% |
| Equity | SEK 1,1M | +2409% |
| Employees | 0 | — |
Legal name
Amplio Pharma AB
Org number
5592371073
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 januari 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget kommer att arbeta med läkemedelsutveckling och utveckling av medicintekniska produkter till exempel diagnostiska produkter. Företaget kommer att bedriva forskning som relaterar till utveckling av läkemedel och medicintekniska produkter och därmed förenlig verksamhet.
Address
Lund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 255 | 89 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 | −134 | −285 | −28 | 1 218 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −134 | −285 | −28 | 1 218 |
| Net financials | — | −49 | −72 | −76 | −92 |
| Profit before tax | −6 | −182 | −357 | −104 | 1 126 |
| Tax | −0 | −0 | −0 | −0 | −101 |
| Net profit | −6 | −182 | −357 | −104 | 1 025 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19 | 1 465 | 1 630 | 1 573 | 2 850 |
| Equity | 19 | 187 | 149 | 45 | 1 129 |
| Long-term debt | 0 | 1 224 | 1 445 | 1 521 | 1 553 |
| Short-term debt | 0 | 55 | 36 | 7 | 167 |
| Total debt | — | 1 279 | 1 481 | 1 528 | 1 720 |
EBITDA margin
1368.5%
This company
15.8%
Market median
+8561% vs market
20212025
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20212025
Return on equity
90.8%
This company
18.4%
Market median
+393% vs market
20212025
Net profit margin
1151.7%
This company
8.1%
Market median
+14119% vs market
20212025
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212025
Debt / equity
1.52×
This company
0.62×
Market median
-145% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-01-01 – 2021-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KA Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
PL Chief Auditor | Chief Auditor | 2022 | — | — |
MM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Truly Translational Sweden AB | Company | 66.0% | 66.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Truly Translational Sweden AB
Amplio Pharma AB Board members of Amplio Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Agneta von Wachenfeldt | Chief Executive Officer | 0 companies |
| Per Lenny Persson | Chief Auditor | 0 companies |
| Marguérite Mascha Mensonides | Deputy Chief Executive Officer | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Per Erik Brunmark | Deputy Board Member | 0 companies |
| Henrik Castenholm Fenger | Board of Directors | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Lars Bukhave Rasmussen | Board of Directors | 0 companies |
| Anna Charlott Brunmark | Chairman | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |